Adaptive Biotechnologies Corporation $ADPT Holdings Raised by Polen Capital Management LLC

Polen Capital Management LLC boosted its stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 11.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 325,767 shares of the company’s stock after buying an additional 34,570 shares during the quarter. Polen Capital Management LLC owned approximately 0.21% of Adaptive Biotechnologies worth $5,290,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Deutsche Bank AG raised its holdings in shares of Adaptive Biotechnologies by 1.2% during the 4th quarter. Deutsche Bank AG now owns 1,734,465 shares of the company’s stock valued at $28,168,000 after purchasing an additional 21,326 shares in the last quarter. Cerity Partners LLC raised its holdings in shares of Adaptive Biotechnologies by 18.6% during the 4th quarter. Cerity Partners LLC now owns 512,869 shares of the company’s stock valued at $8,329,000 after purchasing an additional 80,331 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Adaptive Biotechnologies by 70.6% during the 4th quarter. Franklin Resources Inc. now owns 282,404 shares of the company’s stock valued at $4,586,000 after purchasing an additional 116,884 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Adaptive Biotechnologies by 12.8% during the 4th quarter. JPMorgan Chase & Co. now owns 265,751 shares of the company’s stock valued at $4,316,000 after purchasing an additional 30,083 shares in the last quarter. Finally, Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna bought a new position in shares of Adaptive Biotechnologies during the 4th quarter valued at $273,000. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Price Performance

Shares of ADPT opened at $18.73 on Friday. The company has a market capitalization of $3.00 billion, a PE ratio of -56.76 and a beta of 2.15. Adaptive Biotechnologies Corporation has a one year low of $9.90 and a one year high of $20.76. The company’s fifty day moving average price is $14.50 and its 200 day moving average price is $15.67.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. The firm had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The business’s quarterly revenue was up 35.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.20) EPS. Analysts anticipate that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ADPT has been the topic of a number of recent research reports. JPMorgan Chase & Co. cut their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. BTIG Research restated a “buy” rating and set a $22.00 price target on shares of Adaptive Biotechnologies in a report on Wednesday, May 6th. Wall Street Zen downgraded shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Morgan Stanley cut their price target on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $19.57.

Insider Buying and Selling

In other Adaptive Biotechnologies news, insider Francis Lo sold 39,741 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $17.49, for a total value of $695,070.09. Following the sale, the insider directly owned 250,934 shares in the company, valued at $4,388,835.66. This trade represents a 13.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chad M. Robins sold 83,332 shares of the firm’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $14.41, for a total transaction of $1,200,814.12. Following the completion of the sale, the chief executive officer owned 2,217,781 shares in the company, valued at $31,958,224.21. This represents a 3.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 516,654 shares of company stock worth $7,509,691 in the last quarter. 5.70% of the stock is currently owned by company insiders.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.